Expert Analysis

Hepatitis Coinfection and Opportunistic Infections

Source: CCO Independent Conference Coverage of the 2005 International AIDS Society Conference on HIV Pathogenesis and Treatment*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Hepatitis Coinfection and Opportunistic Infections

Program Director: John P. Phair, MD

Faculty:

Richard E. Chaisson, MD
Bruce Polsky, MD
Jürgen K. Rockstroh, MD

CME CREDIT INFORMATION

Release Date: 09/30/05

Expiration Date: 09/29/06

Physicians: maximum of 1.5 AMA PRA Category 1 Credits™

Registered Nurses: 1.8 Nursing CE credits

Pharmacists: 1.5 contact hours (0.15 CEUs)

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss parameters for treatment success in patients coinfected with HIV and hepatitis B or C.
Recount parameters for treatment selection in patients with HIV/TB coinfection.
Describe sequelae of HIV/HCV coinfection such as development of hepatocellular carcinoma and fibrotic histologic changes.
List factors related to hepatotoxicity in HIV/HCV and HIV/TB coinfection.

Topics covered include:

Acute HCV Infection
Hepatocellular Carcinoma in HCV Monoinfection vs HCV/HIV Coinfection
Treatment Duration in Patients With Chronic HCV/HIV Coinfection
Relationship Between HCV Viral Load and Histology in HCV/HIV-Coinfected Patients
Relationship Between Early HCV Kinetics and SVR in HCV/HIV-Coinfected Patients
Emergence of HCV RNA Positivity Among HCV/HIV-Coinfected Patients Initiating HAART
Hepatotoxicity in HCV/HIV Coinfection
Hepatitis B Virus/HIV Coinfection
Syphilis Among HIV-Infected Patients
Hepatotoxicity Related to Coadministration of HAART and Tuberculosis Treatment
Multidrug Therapy for Tuberculosis in Coinfected Patients
Testing for Tuberculosis in HIV Patients

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.